SECURITIES AND EXCHANGE COMMISSION
                                        
                              Washington, DC  20549
                                        
                                    FORM 8-K
                                        
      CURRENT REPORT     
      
      Pursuant to Section 13 or 15(d) of the
      Securities Exchange Act of 1934
      
     September 7, 1994
      
     Mallinckrodt Group Inc.
      (Exact name of registrant as specified in its charter)
      
     New York  (State or other jurisdiction of incorporation)     
  
                   
      
      1-483 (Commission File Number)
      
      36-1263901 (IRS Employer Identification No.)
      
      7733 Forsyth Boulevard, St. Louis, MO           
      (Address of principal executive offices)             
      
      63105-1820
      (Zip Code)
      
      (314) 854-5200
      Registrant's telephone number,                      
      including area code
            
Item 5.  Other Events
      A press release was issued September 7, 1994.  The text of
  that
      release is as follows:
      
      MALLINCKRODT GROUP SAYS MEDICAL COMPANY PLANS TO RELOCATE A
      MANUFACTURING OPERATION
      
      St. Louis, Missouri, September 7, 1994 -- Mallinckrodt
  Group
      Inc. (NYSE:MKG) announced today that its medical business,
      Mallinckrodt Medical, Inc., plans to move its tracheal tube
      manufacturing operations from Argyle, N.Y., to three other
      locations.
      
         C. Ray Holman, Mallinckrodt Group president and chief
      executive officer, said, "This relocation program is one
  piece
      of a previously announced restructuring that Mallinckrodt
      Medical initiated and recorded in fiscal 1994.  Other
      components of the restructuring include a reorganization of
  the
      company's sales structure, which has been completed, and
  the
      reduction, centralization and standardization of certain
  non-
      sales related functions and management systems to better
      support the reorganized sales structure.  The restructuring
      program will enable Mallinckrodt Medical to maintain strong
      sales and earnings growth."
      
         The medical company's plans call for 12 to 13 percent
      sales growth over the next five years and earnings growth
  of
      approximately 14 to 15 percent.  The growth will result
  from
      the introduction of new products, such as OctreoScan and
      Albunex, which were approved by the U.S. Food and Drug
      Administration in June and August, respectively; volume
  growth
      from existing products; productivity improvement and cost
      reductions from the restructuring.
      
         Mallinckrodt Group Inc., a St. Louis-based Fortune 250
      company, had fiscal 1994 net sales of $1.94 billion. 
  Through
      its three technology-based businesses -- Mallinckrodt
  Chemical
      and Mallinckrodt Medical, both headquartered in the St.
  Louis
      area, and Mallinckrodt Veterinary, headquartered in
  Mundelein,
      Illinois, the company provides human and animal health
  products
      and specialty chemicals.
      
      
      Pursuant to the requirements of the Securities Exchange Act
  of
      1934, the registrant has duly caused this report to be
  signed
      on its behalf by the undersigned thereunto duly authorized.
      
      Mallinckrodt Group Inc.
      
      
      ROGER A. KELLER
      Vice President, Secretary and General Counsel
      
      Date: September 21, 1994